Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort.

[1]  Sabrina Eberhart,et al.  Applied Missing Data Analysis , 2016 .

[2]  T. N. Harrison,et al.  Digoxin and Risk of Death in Adults With Atrial Fibrillation: The ATRIA-CVRN Study , 2013, Circulation. Arrhythmia and electrophysiology.

[3]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[4]  M. Turakhia,et al.  Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. , 2014, Journal of the American College of Cardiology.

[5]  Jeremy Sugarman,et al.  Ethics and regulatory complexities for pragmatic clinical trials. , 2014, JAMA.

[6]  M. Vaduganathan,et al.  The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. , 2014, Journal of the American College of Cardiology.

[7]  J. Nielsen,et al.  ESC Guidelines on cardiac pacing and cardiac resynchronization therapy , 2014 .

[8]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[9]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[10]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[11]  A. Go,et al.  Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure , 2013, Circulation. Cardiovascular quality and outcomes.

[12]  Lluís Mont,et al.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.

[13]  R. Charnigo,et al.  Increased mortality among patients taking digoxin--analysis from the AFFIRM study. , 2013, European heart journal.

[14]  J. Cleland,et al.  Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. , 2013, European heart journal.

[15]  G. Filippatos,et al.  Effect of oral digoxin in high‐risk heart failure patients: a pre‐specified subgroup analysis of the DIG trial , 2013, European journal of heart failure.

[16]  B. Massie,et al.  Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.

[17]  D. DeMets,et al.  Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[18]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[19]  S. Kanji,et al.  Cardiac glycoside toxicity: more than 200 years and counting. , 2012, Critical care clinics.

[20]  B. Gersh,et al.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.

[21]  John Spertus,et al.  Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.

[22]  Peter C Austin,et al.  Report Card on Propensity-Score Matching in the Cardiology Literature From 2004 to 2006: A Systematic Review , 2008, Circulation. Cardiovascular quality and outcomes.

[23]  S. Olsson,et al.  Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data , 2007, Heart.

[24]  Douglas E Schaubel,et al.  A Sequential Stratification Method for Estimating the Effect of a Time‐Dependent Experimental Treatment in Observational Studies , 2006, Biometrics.

[25]  M. Gheorghiade,et al.  Contemporary Use of Digoxin in the Management of Cardiovascular Disorders , 2006, Circulation.

[26]  M. Rich,et al.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. , 2006, European heart journal.

[27]  Harlan M Krumholz,et al.  Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.

[28]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[29]  Rian,et al.  A DOSE-DEPENDENT INCREASE IN MORTALITY WITH VESNARINONE AMONG PATIENTS WITH SEVERE HEART FAILURE , 2000 .

[30]  A. Maggioni,et al.  Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. , 1999, American heart journal.

[31]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[32]  R. Schlant,et al.  MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION. , 1964, The American journal of medicine.